atenolol and losartan

atenolol has been researched along with losartan in 281 studies

Research

Studies (281)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's12 (4.27)18.2507
2000's192 (68.33)29.6817
2010's68 (24.20)24.3611
2020's9 (3.20)2.80

Authors

AuthorsStudies
Funakoshi, J; Kakumoto, M; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Avdeef, A; Tam, KY1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dahlöf, B; Goldberg, AI; Keller, SE; Lim, NY; Makris, L; Sweet, CS1
Goldberg, A; Sweet, C1
Dunlay, MC; Goldberg, AI; Sweet, CS2
Hajj-Ali, AF; Wong, PC1
Hilgenfeldt, U; Schwind, S1
Couch, SJ; Pals, DT1
Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS1
Dahlöf, B; de Faire, U; Devereux, R; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, S; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H1
Brown, MJ1
Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H1
Alesse, E; Bravi, MC; Desideri, G; Ferri, C; Gulino, A; Martinotti, S; Pastore, L; Santucci, A; Tessitore, A; Toniato, E1
Intengan, HD; Park, JB; Schiffrin, EL; Touyz, RM1
Grote, L; Hedner, J; Kraiczi, H; Peker, Y1
Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F1
Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H1
Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM1
Elghozi, JL; Girard, A; Holand, S; Laude, D1
Khazine, F; Simons, O1
Ball, KJ; Stumpe, KO; Williams, PA1
Björnstad, H; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Giles, TD; Palmieri, V; Papademetriou, V; Wachtell, K1
Aalto, T; Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Palmieri, V; Papademetriou, V; Rokkedal, J; Wachtell, K1
Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H1
Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H1
Oparil, S1
Einecke, D1
Hernborg, A; Liedholm, H; Melander, A; Werkö, L1
Järhult, B1
Kahan, T; Nilsson, P1
Schiffrin, EL1
Heinzl, S1
Rapi, J1
Scheen, AJ1
Wiedermann, CJ1
Hamon, M1
Cruickshank, JM1
Bloom, JM1
Brown, MJ; Cockcroft, JR1
Lapeyre-Mestre, M; Montastruc, JL; Pathak, A1
Fuchs, FD1
Fritschka, E; Ludwig, M; Ribeiro, A; Smith, RD; Stapff, M; Stumpe, KO; Tholl, U1
Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A1
Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H1
Malik, RA1
Böhm, S1
González-Juanatey, JR1
Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H1
Van Brabandt, H1
Vandenbroucke, JP2
Dominiak, P; Zidek, W1
Zidek, W1
Lester, MH; Resnick, LM1
Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K1
Karpov, IuA1
Adams, HP1
Schmieder, RE; Schneider, MP1
Armstrong, PW; Borer, J; Fleming, T; Pfeffer, M1
de Boer, RA; Gans, RO; Gansevoort, RT; van Veldhuisen, DJ1
Werkö, L1
Fournier, A; Grossman, E; Messerli, FH1
Achard, JM; Andrejak, M; Fernandez, L; Fournier, A; Oprisiu, R1
Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL1
Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL1
Messerli, FH2
Böhm, M; Fries, R1
Lim, HS; Lip, GY; Nadar, S1
Schunkert, H1
Liebson, PR1
Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Papademetriou, V; Toivonen, L; Viitasalo, M; Wachtell, K1
Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM1
Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S1
Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H1
Aronow, WS1
Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K1
Baumgart, P3
Diener, HC1
Sidorenko, BA; Ugriumova, MO1
Albino-Teixeira, A; Guimarães, S; Morato, M; Moura, D; Sousa, T1
Brainin, M; Finsterer, J; Slany, J; Stöllberger, C1
Arend, A; Aunapuu, M; Ots, M; Pechter, U; Suuroja, T1
Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Zoppi, A1
Ong, HT1
Chong, AY; Lip, GY1
Beloqui, O; Díez, J; González, A; Laviades, C; López, B; Mayor, G; Orbe, J; Páramo, JA; Zalba, G1
Chen, C; Snapinn, SM; Wang, H1
Alderman, MH; Chen, C; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H1
Alderman, MH; Beevers, G; Dahlöf, B; Devereux, RB; Douglas, JG; Edelman, JM; Harris, KE; Julius, S; Kjeldsen, SE; Nesbitt, S; Randall, OS; Wright, JT1
Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K1
Liakishev, AA1
Bratland, B; Gerhardsen, G; Gisholt, K; Kjeldsen, SE; Omvik, P; Risanger, T; Smedsrud, T1
Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Koren, MJ; Liu, JE; Nieminen, MS; Palmieri, V; Wachtell, K; Wright, JT; Zabalgoitia, M1
Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Liu, JE; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K1
Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K1
Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K1
Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H2
Beevers, DG1
Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Snapinn, S; Toivonen, L; Viitasalo, M1
Aunapuu, M; Kullissaar, T; Ots, M; Pechter, U; Riispere, Z; Vihalemm, T; Zilmer, K; Zilmer, M1
Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, P; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K1
Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A1
Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y2
Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K1
Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Olsen, MH; Papademetriou, V; Rokkedal, J; Wachtell, K1
Devereux, RB; Lyle, PA1
Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H1
Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K1
Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H1
Burnier, M; Erne, P; Szucs, TD1
Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K1
Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K1
Bourassa, MG1
Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K1
Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H1
Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H1
Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K1
Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K1
O'Rourke, MF; Safar, ME2
Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH1
Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T1
Bella, JN; Dige-Petersen, H; Ibsen, H; Neland, K; Olsen, MH; Rokkedal, J; Wachtell, K1
Dahlöf, B; Devereux, RB; Franklin, SS; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Olsen, MH; Papademetriou, V; Wachtell, K1
Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H1
Hara, Y; Higaki, J; Miki, T; Ogimoto, A; Ohtsuka, T; Shigematsu, Y1
Nattel, S1
Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Ibsen, H; Nieminen, MS; Olsen, MH; Palmieri, V; Smith, G; Wachtell, K1
Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z1
Weber, MA1
Chao, AC; Chen, YY; Chern, CM; Hsu, HY; Hsu, LC; Hu, HH1
Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y1
Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y1
Band, M; Carr, E; Davies, J; Morris, A; Struthers, A1
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K1
Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM1
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Lyle, PA; Nieminen, MS; Olsen, MH; Wachtell, K1
Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J1
Dahlöf, B; Devereux, RB; Hall, C; Hildebrandt, PR; Ibsen, H; Kjeldsen, SE; Nielsen, OW; Olsen, MH; Wachtell, K; Wergeland, R1
Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K1
Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC1
Björnstad, H; Davidsen, ES; Devereux, RB; Gerdts, E; Lund-Jhansen, P; Omvik, P1
Burke, T; Carides, GW; Hildebrandt, P; Keiding, H1
Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N1
Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Oikarinen, L; Omvik, P; Otterstad, JE; Wachtell, K1
Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H1
Dahlöf, B; Devereux, RB1
Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P1
Chiara Cavallini, M; Palmieri, V; Pini, R1
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K1
Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA1
Chattopadhyay, A; Dahlöf, B; Devereux, RB; Flaa, A; Hille, DA; Høieggen, A; Iversen, EK; Kjeldsen, SE; Lyle, PA; Olsen, MH; Os, I; Smebye, ML1
Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM1
Barba, J; Castellano, JM; Díez, J; González, A; López, B1
Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA1
Bradley, TJ; Colan, SD; Devereux, RB; Dietz, HC; Klein, GL; Lacro, RV; Li, JS; Mahony, L; Minich, LL; Paridon, SM; Pearson, GD; Printz, BF; Pyeritz, RE; Radojewski, E; Roman, MJ; Saul, JP; Stylianou, MP; Wruck, LM1
Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM1
Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S1
Bang, LE; Hildebrandt, PR; Ibsen, H; Larsen, J; Olsen, MH; Tuxen, C; Wachtell, K; Wiinberg, N1
Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K1
Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K1
Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I1
Garzoni, LR; Henriques, Md; Lessa, MA; Levy, BI; Nascimento, AR; Rodrigues, CA; Sabino, B; Tibiriçá, E1
Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K1
Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K1
Cramariuc, D; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Wachtell, K1
Mourad, JJ; Waeber, B1
Avanza, AC; Mansur, AP; Ramires, JA1
Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H1
Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M2
Dahlöf, B; Devereux, RB; Franklin, S; Gerdts, E; Nieminen, M; Papademetriou, V; Rieck, A; Wachtell, K1
Dahlöf, B; Devereux, RB; John, M; Kjeldsen, SE; Morin, DP; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M1
Brody, R; Grossman, E; Peleg, E; Sharabi, Y1
Gopinathannair, R; Olshansky, B; Sullivan, RM1
Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K1
Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M1
Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Okin, PM1
Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H1
Adachi, K; Furuta, K; Kinoshita, Y; Koshino, K; Miki, M; Morita, T; Nakata, S; Ohara, S; Tanimura, T; Yoshida, K1
Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM1
Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K1
Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP1
Aurigemma, GP; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Olsen, MH; Palmieri, V; Rokkedal, JE; Wachtell, K1
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K2
Cameron, A; Ewen, M; Laing, RO; van Mourik, MS1
Angeli, F; Mazzotta, G; Reboldi, G; Verdecchia, P1
Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Okin, PM1
de Cavanagh, EM; Ferder, LF; Ferder, MD; Inserra, F; Stella, IY; Toblli, JE1
Cunha, FM; Fontes, V; Gusmão, JL; Ignez, EC; Mano, GP; Mion, D; Nishiura, JL; Ortega, KC; Pierin, AM; Segre, CA; Ventura, CG1
Chavan, UB; Deshpande, AD; Dighe, SB; Jagdale, SN; Kothapalli, LP; Nanda, RK; Thomas, AB1
Hosseini, F; Mahmoudian, M; Nemati, F; Rahbar-Roshandel, N; Shafiei, M1
Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G1
Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Kontula, K; Os, I; Saijonmaa, O; Silventoinen, K1
Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K1
Jan, MY; Wang, SH; Wang, WK; Wang, YY1
Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K1
Dahlöf, B; Devereux, RB; Kjeldsen, SE; Lindholm, LH; Okin, PM1
Berwanger, O; Mion Júnior, D; Ortega, KC; Silva, GV; Tsuji, RL1
Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM1
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Olsen, MH; Ruwald, AC; Sehestedt, T; Wachtell, K; Westergaard, B1
Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Greve, AM; Lønnebakken, MT; Nieminen, MS; Okin, PM; Olsen, MH; Omvik, P; Palmieri, V; Wachtell, K1
Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K1
Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH1
Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Guey, LT; Heydarian, H; Lacro, RV; Lai, WW; Levine, JC; Lewin, MB; Marcus, E; Mart, CR; Pearson, GD; Pignatelli, RH; Printz, BF; Selamet Tierney, ES; Sharkey, AM; Shirali, GS; Sleeper, LA; Srivastava, S1
Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP1
Benson, DW; Bradley, TJ; De Backer, J; Dietz, HC; Forbus, GA; Gelb, BD; Guey, LT; Klein, GL; Lacro, RV; Lai, WW; Levine, JC; Lewin, MB; Loeys, BL; Mahony, L; Markham, LW; Paridon, SM; Pearson, GD; Pierpont, ME; Radojewski, E; Selamet Tierney, ES; Sharkey, AM; Wechsler, SB; Yetman, AT1
Abdelhai, YM; Boman, K; Dahlöf, B; De Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Wachtell, K1
Jeffers, BW; Wang, JG; Yan, P1
Aurigemma, GP; Bang, CN; Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Køber, L; Wachtell, K1
Anhê, GF; Antunes, E; Calmasini, F; Faria, Jde A; Mónica, FZ; Moscoso, JA; Ramos-Filho, AC1
Avasthi, R; Dastidaro, DG; Guha, S; Majumdar, D; Mani, S; Mitra, M; Mondal, MM; Mookerjee, S; Narain, VS; Rajendiran, C; Ray, S; Saha, J1
Bowen, JM; Connolly, HM1
Atz, AM; Benson, DW; Bradley, TJ; Braverman, AC; Chen, S; Colan, SD; De Backer, J; Dietz, HC; Gelb, BD; Grossfeld, PD; Klein, GL; Lacro, RV; Lai, WW; Levine, JC; Liou, A; Loeys, BL; Mahony, L; Markham, LW; Olson, AK; Paridon, SM; Pearson, GD; Pemberton, VL; Pierpont, ME; Pyeritz, RE; Radojewski, E; Roman, MJ; Selamet Tierney, ES; Sharkey, AM; Sleeper, LA; Stylianou, MP; Wechsler, SB; Yetman, AT; Young, LT1
Alghamdi, MH; Kiess, M; Potts, JE; Potts, MT; Raffin, LA; Sandor, GG; van Breemen, C; Williams, LD1
Dietz, HC; Lacro, RV; Mahony, L1
Elefteriades, JA; Mukherjee, SK; Ziganshin, BA1
Mohiaddin, R; Pepper, J; Treasure, T1
Mallat, Z; Tedgui, A1
Bhatt, AB; Buck, JS; Creager, MA; Gauvreau, K; Kadivar, S; Milian, J; Singh, MN; Zuflacht, JP1
Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K1
Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K1
Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K1
Beau-Salinas, F; Bejan-Angoulvant, T; Jonville-Béra, AP; Lengellé, C1
Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K1
Centeno, J; Cortina, J; Evangelista, A; Ferreira-González, I; Forteza, A; García-Dorado, D; Gracia, T; Gutiérrez, L; Rodríguez-Palomares, J; Rufilanchas, JJ; Sánchez, V; Sanz, P; Teixidó-Turà, G1
Adji, A; O'Rourke, MF; Weber, T1
Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM1
Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Midtbø, H; Wachtell, K1
Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM1
Devereux, RB; Kjeldsen, SE; Okin, PM2
Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Heydarian, H; Hoskoppal, A; Lacro, RV; Lai, WW; Levine, JC; Liou, A; Marcus, E; Nutting, A; Olson, AK; Parra, DA; Pearson, GD; Pierpont, ME; Printz, BF; Pyeritz, RE; Ravekes, W; Roman, MJ; Selamet Tierney, ES; Sharkey, AM; Sleeper, LA; Srivastava, S; Young, L1
Bonomini, HIM; De Sousa, FB; Lopes, JF; Meira, LHR; Soares, GAB1
de Moura Leão, MF; de Oliveira, LFS; Duarte, JA; Machado, MM; Piccoli, JDCE; Sauzen, PD1
Crosson, JE; Czosek, RJ; Lacro, RV; Love, BA; Mah, DY; McCrindle, BW; Muiño-Mosquera, L; Olson, AK; Pilcher, TA; Shah, MJ; Sleeper, LA; Tierney, ESS; Wechsler, SB; Young, LT1
Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G1
Isselbacher, EM1
Atz, TW; Bradley, TJ; Cappella, E; De Nobele, S; Groh, GK; Hamstra, MS; Handisides, JC; Hollenbeck-Pringle, D; Korsin, R; Lacro, RV; Levine, JC; Lindauer, B; Liou, A; Markham, LW; Morrison, T; Mussatto, KA; Neal, MKM; Olson, AK; Pemberton, VL; Pierpont, MEM; Pyeritz, RE; Radojewski, EA; Roman, MJ; Trachtenberg, FL; Uzark, K; Xu, M1
Dietz, HC; Forbus, GA; Gelb, BD; Goldmuntz, E; Hoskoppal, A; James, J; Lacro, RV; Lee, TM; Levine, JC; Li, JS; Loeys, BL; Markham, LW; Meester, JAN; Mital, S; Morris, SA; Mosley, JD; Olson, AK; Renard, M; Roden, DM; Shaffer, CM; Sharkey, A; Sleeper, LA; Van Driest, SL; Young, L1
Atz, AM; Cappella, E; Cnota, JF; Dagincourt, N; De Nobele, S; Grima, J; Hamstra, MS; Hollenbeck-Pringle, D; King, M; Korsin, R; Lacro, RV; Lambert, LM; MacCarrick, G; MacNeal, MK; Markham, LW; Pemberton, VL; Sylvester, DM; Trachtenberg, FL; Walter, P; Xu, M1
Colan, SD; Flyer, JN; Lacro, RV; Singh, MN; Sleeper, LA1
Ayers, R; Iannucci, G; Kelleman, M; McCracken, C; Oster, ME1
Begum, S; Ferdousi, S; Sultana, S1
Correia, AT; de Oliveira, TMN; Guimarães, LL; Pisetta, AM; Roveri, V1
Correia, AT; Guimarães, LL; Roveri, V; Toma, W1
Carmichael, HL; Cox, DA; Minich, LL; Ou, Z; Robertson, DM; Selamet Tierney, ES; Truong, DT; Williams, RV1
A Wartolowska, K; André, E; Biessels, GJ; Bousser, MG; Dichgans, M; Duering, M; Kerkhofs, D; Kopczak, A; Mansmann, U; Middeke, M; N Doubal, F; Norrving, B; Onkenhout, L; Rothwell, PM; S Stringer, M; Staals, J; Thrippleton, MJ; van den Brink, H; van Dinther, M; van Oostenbrugge, R; W Blair, G; Wardlaw, JM; Webb, AJ1

Reviews

15 review(s) available for atenolol and losartan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Irbesartan treatment in hypertension.
    Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Enalapril; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles

1998
[Results from the LIFE study: promising effects of new hypertensive agents].
    Lakartidningen, 2002, Apr-18, Volume: 99, Issue:16

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome

2002
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
    The Canadian journal of cardiology, 2002, Volume: 18 Suppl A

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biphenyl Compounds; Cilazapril; Humans; Hypertension; Irbesartan; Losartan; Perindopril; Tetrazoles

2002
[Irbesartan: a new possibility in the treatment of hypertension].
    Orvosi hetilap, 2002, May-26, Volume: 143, Issue:21

    Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2002
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
    Kardiologiia, 2002, Volume: 42, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diastole; Diuretics; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Losartan; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Systole; Tetrazoles; Time Factors

2002
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
    Medizinische Klinik (Munich, Germany : 1983), 2003, Apr-15, Volume: 98, Issue:4

    Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studies; Heart Failure; Heparin, Low-Molecular-Weight; Humans; Hypertension; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Losartan; Magnetic Resonance Angiography; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Primary Prevention; Risk Factors; Sex Factors; Stents; Thrombolytic Therapy; Time Factors; Vitamins

2003
Implications of the LIFE trial.
    Expert opinion on investigational drugs, 2003, Volume: 12, Issue:5

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Diabetes Complications; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome

2003
[New perspectives of the use of angiotensin II receptor blocker].
    Kardiologiia, 2003, Volume: 43, Issue:6

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Losartan; Receptors, Angiotensin

2003
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic

2004
The role of the new beta-blockers in treating cardiovascular disease.
    American journal of hypertension, 2005, Volume: 18, Issue:12 Pt 2

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Cardiovascular Diseases; Clinical Trials as Topic; Enalapril; Ethanolamines; Female; Heart Failure; Hemodynamics; Humans; Hypertension; Labetalol; Losartan; Male; Metoprolol; Middle Aged; Nebivolol; Nifedipine; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Sympathomimetics

2005
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Current medical research and opinion, 2007, Volume: 23, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cardiovascular Agents; Cohort Studies; Drug Utilization; Endothelium, Vascular; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Models, Biological; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Precursors; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Stroke; Thrombosis; Treatment Outcome

2007
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1995, Volume: 13, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Cough; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Felodipine; Female; Headache; Humans; Hypertension; Incidence; Losartan; Male; Middle Aged; Respiratory Tract Infections

1995
Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2013, Volume: 26, Issue:6

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Atenolol; Chi-Square Distribution; Child; Child, Preschool; Echocardiography; Female; Humans; Infant; Logistic Models; Losartan; Male; Marfan Syndrome; Reproducibility of Results

2013
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
    Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:5

    Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Enalapril; Humans; Hypertension; Lisinopril; Losartan; Randomized Controlled Trials as Topic

2014

Trials

133 trial(s) available for atenolol and losartan

ArticleYear
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
    American journal of hypertension, 1995, Volume: 8, Issue:6

    Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Prospective Studies; Pulse; Tetrazoles; Time Factors

1995
Efficacy and safety of losartan.
    The Canadian journal of cardiology, 1995, Volume: 11 Suppl F

    Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enalapril; Felodipine; Humans; Hypertension; Imidazoles; Losartan; Placebos; Tetrazoles

1995
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    The American journal of cardiology, 1995, Apr-15, Volume: 75, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asthenia; Atenolol; Biphenyl Compounds; Cough; Dizziness; Double-Blind Method; Fatigue; Felodipine; Female; Headache; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Placebos; Respiratory Tract Infections; Safety; Tetrazoles

1995
Losartan potassium as initial therapy in patients with severe hypertension.
    Journal of human hypertension, 1995, Volume: 9, Issue:11

    Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles; Treatment Outcome

1995
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    American journal of hypertension, 1997, Volume: 10, Issue:7 Pt 1

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Losartan; Male; Middle Aged; Research Design; Tetrazoles; Treatment Outcome

1997
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
    Hypertension (Dallas, Tex. : 1979), 1998, Volume: 32, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Body Mass Index; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Sex Factors

1998
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
    Circulation, 2000, Apr-11, Volume: 101, Issue:14

    Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; Buttocks; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Vascular Resistance; Vasodilation

2000
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
    American journal of respiratory and critical care medicine, 2000, Volume: 161, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Diuretics; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Single-Blind Method; Sleep Apnea, Obstructive; Sodium Chloride Symporter Inhibitors

2000
The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
    Journal of hypertension, 2000, Volume: 18, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Systole; Treatment Outcome

2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
    American journal of hypertension, 2000, Volume: 13, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies

2000
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:5

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis

2000
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Circulation, 2002, Mar-05, Volume: 105, Issue:9

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Atria; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Multivariate Analysis; Remission Induction; Treatment Outcome; Ventricular Function, Left

2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged

2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Middle Aged; Regression Analysis

2002
Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?
    Current hypertension reports, 2002, Volume: 4, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Humans; Hypertension; Losartan; Middle Aged

2002
Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study.
    Clinical therapeutics, 2002, Volume: 24, Issue:7

    Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Treatment Outcome; Tunica Intima; Tunica Media

2002
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Journal of hypertension, 2002, Volume: 20, Issue:9

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Neurotransmitter Agents; Safety

2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
    Journal of hypertension, 2002, Volume: 20, Issue:9

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Middle Aged; Prospective Studies; Risk Assessment

2002
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
    Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19 Suppl 5

    Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Protocols; Diabetes Complications; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Morbidity; Risk

2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    JAMA, 2002, Sep-25, Volume: 288, Issue:12

    Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Stroke; Systole; Treatment Outcome

2002
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    American heart journal, 2002, Volume: 144, Issue:6

    Topics: Aged; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Ultrasonography; Ventricular Function, Left

2002
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ugeskrift for laeger, 2003, Jan-27, Volume: 165, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors

2003
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ugeskrift for laeger, 2003, Jan-27, Volume: 165, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors

2003
[Reduction of cardiovascular events with lorsartan? The LIFE Study].
    Der Internist, 2003, Volume: 44, Issue:3

    Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cerebral Infarction; Double-Blind Method; Humans; Hypertension; Losartan; Middle Aged; Myocardial Infarction; Receptor, Angiotensin, Type 1; Survival Rate; Treatment Outcome

2003
LIFE and ARBITER.
    Preventive cardiology, 2003,Spring, Volume: 6, Issue:2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome

2003
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    American heart journal, 2003, Volume: 145, Issue:5

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Remission Induction; Single-Blind Method

2003
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Clinical therapeutics, 2003, Volume: 25, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Losartan; Male; Middle Aged; Regression Analysis; Risk Factors

2003
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Circulation, 2003, Aug-12, Volume: 108, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Diabetes Complications; Double-Blind Method; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Racial Groups; Remission Induction; Risk Factors; Sex Factors; Treatment Outcome

2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
    Annals of internal medicine, 2003, Aug-05, Volume: 139, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2003
Influence of losartan and atenolol on memory function in very elderly hypertensive patients.
    Journal of human hypertension, 2003, Volume: 17, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cognition; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Memory; Psychological Tests

2003
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
    Kidney international, 2004, Volume: 65, Issue:3

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Endpoint Determination; Female; Follow-Up Studies; Hemoglobins; Humans; Hypertension, Renal; Losartan; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Treatment Outcome; Uric Acid

2004
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
    Journal of the American College of Cardiology, 2004, Mar-17, Volume: 43, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Atenolol; Black People; Blood Pressure; Drug Therapy, Combination; Europe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Treatment Outcome; United States; White People

2004
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Stroke

2004
[Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Results of LIFE study].
    Kardiologiia, 2003, Volume: 43, Issue:12

    Topics: Anti-Arrhythmia Agents; Atenolol; Humans; Hypertrophy, Left Ventricular; Losartan; Remission Induction

2003
[Treatment of hypertension in patients with left ventricular hypertrophy].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2004, Mar-18, Volume: 124, Issue:6

    Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2004
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Remission Induction; Sex Factors; Time Factors; Ultrasonography

2004
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Time Factors

2004
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Catecholamines; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Time Factors

2004
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Remission Induction; Time Factors; Ultrasonography

2004
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Treatment Outcome

2004
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
    Journal of hypertension, 2004, Volume: 22, Issue:8

    Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Stroke; Ultrasonography

2004
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; Collagen; Double-Blind Method; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardium; Peptide Fragments; Treatment Outcome; Ultrasonography

2004
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
    Journal of hypertension, 2004, Volume: 22, Issue:9

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Risk Factors; Stroke

2004
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Circulation, 2004, Sep-14, Volume: 110, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Organ Size; Prospective Studies; Treatment Outcome; Ultrasonography

2004
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
    The American journal of cardiology, 2004, Oct-15, Volume: 94, Issue:8

    Topics: Aged; Aged, 80 and over; Aortic Valve; Atenolol; Female; Heart Valve Diseases; Humans; Losartan; Male; Middle Aged; Sclerosis

2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Morbidity; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ultrasonography; Ventricular Remodeling

2004
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Severity of Illness Index; Stroke; Treatment Outcome

2005
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Severity of Illness Index

2005
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Journal of the American College of Cardiology, 2005, Mar-01, Volume: 45, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Survival Analysis

2005
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Journal of the American College of Cardiology, 2005, Mar-01, Volume: 45, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Atrial Fibrillation; Cause of Death; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Secondary Prevention; Stroke; Survival Rate

2005
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Blood pressure, 2004, Volume: 13, Issue:6

    Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Myocardial Infarction; Regression Analysis; Smoking; Stroke

2004
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
    Journal of hypertension, 2005, Volume: 23, Issue:4

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Forearm; Humans; Hypertension; Insulin; Insulin Resistance; Losartan; Middle Aged; Peripheral Vascular Diseases; Vascular Resistance

2005
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
    Journal of clinical hypertension (Greenwich, Conn.), 2005, Volume: 7, Issue:3

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epidemiologic; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Multicenter Studies as Topic; Stroke; Systole; Treatment Outcome

2005
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
    Journal of hypertension, 2005, Volume: 23, Issue:5

    Topics: Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments

2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
    Circulation, 2005, Apr-19, Volume: 111, Issue:15

    Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Obesity; Proportional Hazards Models; Risk Assessment; Somatotypes

2005
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
    Blood pressure, 2005, Volume: 14, Issue:3

    Topics: Aged; Atenolol; Blood Pressure; Carotid Arteries; Female; Humans; Hypertension; Losartan; Male; Time; Treatment Outcome; Tunica Intima; Ultrasonography

2005
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
    Journal of the American College of Cardiology, 2005, Sep-06, Volume: 46, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Treatment Outcome

2005
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
    Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:7

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Follow-Up Studies; Heart Rate; Humans; Hypertension; Losartan; Middle Aged; Prospective Studies; Treatment Outcome

2005
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
    American journal of hypertension, 2005, Volume: 18, Issue:11

    Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Predictive Value of Tests; Prognosis; Risk Factors; Sclerosis; Survival Analysis; Treatment Outcome

2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    The American journal of cardiology, 2005, Dec-01, Volume: 96, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome

2005
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
    Journal of cardiovascular pharmacology, 2006, Volume: 47, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Time Factors; Treatment Outcome

2006
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
    Diabetes care, 2006, Volume: 29, Issue:3

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Predictive Value of Tests; Risk; Treatment Outcome

2006
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
    Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenolol; Carotid Artery Diseases; Disease Progression; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Stroke; Time Factors

2006
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2005, Volume: 6, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Hemodynamics; Humans; Hypertension; Losartan

2005
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Circulation, 2006, Mar-28, Volume: 113, Issue:12

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Treatment Outcome

2006
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Journal of human hypertension, 2006, Volume: 20, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome

2006
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Journal of hypertension, 2006, Volume: 24, Issue:8

    Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Creatinine; Endpoint Determination; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; ROC Curve; Scandinavian and Nordic Countries

2006
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    JAMA, 2006, Sep-13, Volume: 296, Issue:10

    Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Risk

2006
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
    Blood pressure, 2006, Volume: 15, Issue:4

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Echocardiography, Doppler, Color; Electrocardiography; Exercise; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Oxygen Consumption; Physical Endurance

2006
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
    Blood pressure, 2006, Volume: 15, Issue:4

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Biomarkers; Blood Pressure; Female; Fibrosis; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Procollagen

2006
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:2

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Risk Assessment; Stroke

2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Current medical research and opinion, 2007, Volume: 23, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Pulse; Systole; Treatment Outcome

2007
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Journal of hypertension, 2007, Volume: 25, Issue:4

    Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Dinoprost; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypertension; Insulin Resistance; Losartan; Male; Middle Aged; Oxidative Stress; Regional Blood Flow; Research Design; Treatment Outcome; Vasodilation

2007
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Circulation, 2007, Aug-14, Volume: 116, Issue:7

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2007
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Clinical therapeutics, 2007, Volume: 29, Issue:5

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analysis; Endpoint Determination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Life Expectancy; Losartan; Male; Middle Aged; Netherlands; Risk; Stroke

2007
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    The American journal of cardiology, 2007, Sep-01, Volume: 100, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Stroke

2007
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Annals of internal medicine, 2007, Sep-04, Volume: 147, Issue:5

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2007
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5

    Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; Blood Pressure; Cytokines; Diastole; Female; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Systole; Ultrasonography

2007
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Journal of internal medicine, 2007, Volume: 262, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Epidemiologic Methods; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Motor Activity; Myocardial Infarction; Treatment Outcome

2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
    American heart journal, 2007, Volume: 154, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Atenolol; Humans; Losartan; Marfan Syndrome; Outcome Assessment, Health Care; Research Design

2007
Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy.
    Blood pressure, 2007, Volume: 16, Issue:6

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Time Factors

2007
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
    American journal of hypertension, 2008, Volume: 21, Issue:3

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk Factors; Severity of Illness Index

2008
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography, Doppler; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Linear Models; Losartan; Male; Middle Aged; Prevalence; Sex Characteristics; Sex Distribution; Systole

2008
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:4

    Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Risk Reduction Behavior; Sex Distribution; Stroke

2008
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Journal of hypertension, 2008, Volume: 26, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis

2008
Efficacy of exercise, losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy.
    Journal of human hypertension, 2009, Volume: 23, Issue:4

    Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Enalapril; Exercise Test; Exercise Therapy; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Oxazoles; Renin-Angiotensin System; Rilmenidine; Sympathetic Nervous System

2009
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    American heart journal, 2009, Volume: 157, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Hemoglobins; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis

2009
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Circulation, 2009, Apr-14, Volume: 119, Issue:14

    Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Medical History Taking; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Stress, Mechanical; Systole

2009
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
    Blood pressure, 2009, Volume: 18, Issue:4

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke Volume; Ventricular Function, Left

2009
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
    European heart journal, 2009, Volume: 30, Issue:23

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardiography; Epidemiologic Methods; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2009
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Circulation. Arrhythmia and electrophysiology, 2008, Volume: 1, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2008
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Double-Blind Method; Female; Fibrinolysis; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Renin-Angiotensin System; Thrombophilia; Tissue Plasminogen Activator; von Willebrand Factor

2010
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study.
    Journal of hypertension, 2009, Volume: 27, Issue:11

    Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Heart Failure; Humans; Incidence; Likelihood Functions; Losartan; Male; Middle Aged; Placebos

2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
    Blood pressure, 2009, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2009
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    American journal of hypertension, 2010, Volume: 23, Issue:8

    Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Uric Acid

2010
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
    European heart journal, 2010, Volume: 31, Issue:18

    Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Treatment Outcome

2010
How to avoid discontinuation of antihypertensive treatment: The experience in São Paulo, Brazil.
    Clinics (Sao Paulo, Brazil), 2010, Volume: 65, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Clinical Protocols; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Medication Adherence; Middle Aged; Telephone

2010
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
    European journal of heart failure, 2011, Volume: 13, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Assessment

2011
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
    Revista espanola de cardiologia, 2011, Volume: 64, Issue:6

    Topics: Adolescent; Adult; Antihypertensive Agents; Aorta; Aortic Diseases; Atenolol; Child; Child, Preschool; Double-Blind Method; Electrocardiography; Female; Humans; Losartan; Magnetic Resonance Imaging; Male; Marfan Syndrome; Middle Aged; Young Adult

2011
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Journal of human hypertension, 2011, Volume: 25, Issue:12

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Leukocytes; Losartan; Male; Middle Aged; Risk Factors; Telomere; Treatment Outcome

2011
In-treatment stroke volume predicts cardiovascular risk in hypertension.
    Journal of hypertension, 2011, Volume: 29, Issue:8

    Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk Factors; Stroke; Stroke Volume; Ventricular Function, Left

2011
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
    Blood pressure, 2012, Volume: 21, Issue:1

    Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Smoking

2012
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
    Blood pressure, 2012, Volume: 21, Issue:3

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Hypokalemia; Losartan; Male; Prospective Studies; Ultrasonography

2012
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Journal of hypertension, 2012, Volume: 30, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome; United States

2012
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Journal of hypertension, 2012, Volume: 30, Issue:6

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Losartan; Male; Middle Aged; Risk Factors

2012
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
    American journal of hypertension, 2012, Volume: 25, Issue:9

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2012
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
    American journal of hypertension, 2012, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Regression Analysis; Treatment Outcome

2012
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:2

    Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Blind Method; Echocardiography; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Regression Analysis; Risk Factors

2012
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Mayo Clinic proceedings, 2013, Volume: 88, Issue:3

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Atenolol; Child; Dilatation, Pathologic; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Losartan; Male; Marfan Syndrome; Pilot Projects; Propranolol; Treatment Outcome; Young Adult

2013
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
    Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:10

    Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Risk Factors

2013
Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
    American heart journal, 2013, Volume: 165, Issue:5

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm, Thoracic; Atenolol; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Losartan; Male; Marfan Syndrome; Retrospective Studies; Treatment Outcome; Young Adult

2013
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
    Blood pressure, 2014, Volume: 23, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Systole

2014
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
    Circulation. Cardiovascular imaging, 2014, Volume: 7, Issue:3

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; Death; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Organ Size; Proportional Hazards Models; Stroke

2014
A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension.
    Journal of the Indian Medical Association, 2013, Volume: 111, Issue:12

    Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; White Coat Hypertension

2013
Atenolol versus losartan in children and young adults with Marfan's syndrome.
    The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Aortic Valve Insufficiency; Atenolol; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Linear Models; Losartan; Male; Marfan Syndrome; Treatment Outcome; Young Adult

2014
A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
    International journal of cardiology, 2015, Jan-20, Volume: 179

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Atenolol; Double-Blind Method; Echocardiography; Endothelium, Vascular; Female; Humans; Loeys-Dietz Syndrome; Losartan; Male; Marfan Syndrome; Pilot Projects; Pulse Wave Analysis; Treatment Outcome

2015
Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
    Vascular medicine (London, England), 2015, Volume: 20, Issue:4

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Atenolol; Boston; Double-Blind Method; Echocardiography, Doppler, Pulsed; Female; Humans; Losartan; Male; Manometry; Marfan Syndrome; Middle Aged; Pulse Wave Analysis; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left

2015
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
    Journal of hypertension, 2015, Volume: 33, Issue:7

    Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Digoxin; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Lipoproteins, HDL; Losartan; Male; Middle Aged; Risk

2015
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:2

    Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Regression Analysis; Risk Factors; Systole; Treatment Outcome

2015
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
    Journal of hypertension, 2015, Volume: 33, Issue:12

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Creatinine; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Ultrasonography

2015
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:5

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Female; Heart Rate; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Oxygen; Prevalence; Stroke; Treatment Outcome

2015
Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
    European heart journal, 2016, Mar-21, Volume: 37, Issue:12

    Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Child; Child, Preschool; Double-Blind Method; Humans; Losartan; Magnetic Resonance Angiography; Magnetic Resonance Imaging, Cine; Marfan Syndrome; Middle Aged; Treatment Outcome; Young Adult

2016
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
    Blood pressure, 2017, Volume: 26, Issue:3

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Stroke; Stroke Volume; Vascular Stiffness

2017
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Journal of the American Heart Association, 2017, Nov-18, Volume: 6, Issue:11

    Topics: Aged; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Risk Factors; Survival Rate; Treatment Outcome; United States

2017
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.
    Journal of hypertension, 2018, Volume: 36, Issue:4

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mortality; Patient Care Planning; Proportional Hazards Models; Systole; Treatment Outcome; United States

2018
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
    European heart journal. Quality of care & clinical outcomes, 2016, 10-01, Volume: 2, Issue:4

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Function Tests; Losartan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors

2016
Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.
    The American journal of cardiology, 2018, 05-01, Volume: 121, Issue:9

    Topics: Adolescent; Aorta; Aortic Diseases; Atenolol; Cardiac Imaging Techniques; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Linear Models; Losartan; Marfan Syndrome; Prognosis; Proportional Hazards Models; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome; Vascular Stiffness

2018
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
    Journal of the American College of Cardiology, 2018, 10-02, Volume: 72, Issue:14

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Aortic Dissection; Atenolol; Dilatation, Pathologic; Disease Progression; Female; Follow-Up Studies; Humans; Losartan; Magnetic Resonance Imaging, Cine; Male; Marfan Syndrome; Young Adult

2018
Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.
    The Journal of pediatrics, 2019, Volume: 204

    Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Child; Child, Preschool; Female; Health Status Indicators; Humans; Losartan; Male; Marfan Syndrome; Patient Reported Outcome Measures; Quality of Life; Severity of Illness Index; Young Adult

2019
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
    The Journal of pediatrics, 2020, Volume: 222

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Atenolol; Child; Child, Preschool; Cytochrome P-450 CYP2C9; DNA; Female; Follow-Up Studies; Gene Expression Regulation; Genotype; Humans; Infant; Losartan; Male; Marfan Syndrome; Receptors, Adrenergic, beta-1; Retrospective Studies; Young Adult

2020
Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
    Pediatric cardiology, 2023, Volume: 44, Issue:3

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Child; Female; Humans; Losartan; Male; Marfan Syndrome; Prescriptions; Young Adult

2023
The EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial.
    European stroke journal, 2023, Volume: 8, Issue:1

    Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-Over Studies; Humans; Losartan; Prospective Studies; Randomized Controlled Trials as Topic

2023

Other Studies

133 other study(ies) available for atenolol and losartan

ArticleYear
Interaction of digoxin with antihypertensive drugs via MDR1.
    Life sciences, 2002, Feb-15, Volume: 70, Issue:13

    Topics: Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Digoxin; Drug Interactions; Humans; Time Factors

2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
    Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9

    Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Beta adrenoceptor blockade in rabbit inhibits the renin-releasing effect of AT1 receptor antagonist losartan.
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Biphenyl Compounds; Blood Pressure; Heart Rate; Imidazoles; Indomethacin; Losartan; Male; Rabbits; Renin; Tetrazoles

1993
Angiotensin II is the mediator of the increase in hepatic angiotensinogen synthesis after bilateral nephrectomy.
    The American journal of physiology, 1993, Volume: 265, Issue:3 Pt 1

    Topics: Adrenalectomy; Angiotensin II; Angiotensinogen; Animals; Atenolol; Biphenyl Compounds; Imidazoles; Kidney; Liver; Losartan; Male; Nephrectomy; Osmolar Concentration; Postoperative Period; Rats; Rats, Wistar; Renin; Tetrazoles; Time Factors

1993
Renin release induced by losartan (DuP 753), an angiotensin II receptor antagonist.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 1993, Volume: 15, Issue:1

    Topics: Angiotensin Receptor Antagonists; Animals; Atenolol; Biphenyl Compounds; Dose-Response Relationship, Drug; Feedback; Imidazoles; Indomethacin; Injections, Intravenous; Losartan; Male; Meclofenamic Acid; Propranolol; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Angiotensin; Renin; Sympathetic Nervous System; Tetrazoles

1993
Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.
    Circulation, 1999, Oct-12, Volume: 100, Issue:15

    Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cells, Cultured; Endothelium, Vascular; Female; Gene Expression Regulation; Humans; Hypertension; Intercellular Adhesion Molecule-1; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Umbilical Veins

1999
Antihypertensive monotherapy and cardiovascular responses to an acoustic startle stimulus.
    Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:1

    Topics: Acoustic Stimulation; Adrenergic alpha-Agonists; Analysis of Variance; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Prazosin; Reflex, Startle; Stroke Volume; Vascular Resistance

2001
[When hypertension damages microcirculation. A-II-antagonist corrects damage, beta blocker does not].
    MMW Fortschritte der Medizin, 2001, Mar-01, Volume: 143, Issue:9

    Topics: Atenolol; Clinical Trials as Topic; Follow-Up Studies; Humans; Hypertension; Losartan; Microcirculation; Vascular Resistance

2001
[A possible adverse effect from the association of losartan-mefenamic acid in hemodialysis].
    Nephrologie, 2001, Volume: 22, Issue:2

    Topics: Adult; Antihypertensive Agents; Atenolol; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Furosemide; Glomerulonephritis, IGA; Humans; Hypertension; Losartan; Mefenamic Acid; Renal Dialysis

2001
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2001, Volume: 19, Issue:1

    Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Imidazoles; Losartan; Multicenter Studies as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles

2001
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
    The American journal of cardiology, 2002, Feb-15, Volume: 89, Issue:4

    Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Pulse; Randomized Controlled Trials as Topic

2002
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
    MMW Fortschritte der Medizin, 2002, Apr-04, Volume: 144, Issue:14

    Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Prognosis; Randomized Controlled Trials as Topic; Stroke; Survival Rate

2002
ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
    Geriatrics, 2002, Volume: 57, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome

2002
[Marketing of researchers--lack of judgment or a new trend?].
    Lakartidningen, 2002, Apr-25, Volume: 99, Issue:17

    Topics: Advertising; Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Ethics, Medical; Evidence-Based Medicine; Humans; Losartan; Marketing of Health Services; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Research Personnel; Sweden

2002
[Marketing of the LIFE trial anticipates evaluation of the drug].
    Lakartidningen, 2002, Apr-25, Volume: 99, Issue:17

    Topics: Advertising; Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Ethics, Medical; Humans; Losartan; Marketing of Health Services; Randomized Controlled Trials as Topic; Sweden

2002
[LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
    Medizinische Monatsschrift fur Pharmazeuten, 2002, Volume: 25, Issue:5

    Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Risk Factors

2002
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
    Revue medicale de Liege, 2002, Volume: 57, Issue:4

    Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; Humans; Hypertension; Losartan; Male; Myocardial Infarction; Stroke; Treatment Outcome

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Losartan

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Heart Rate; Humans; Losartan; Risk Factors

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Losartan; Reproducibility of Results

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Humans; Losartan; Natriuretic Peptide, Brain

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Antihypertensive Agents; Atenolol; Endpoint Determination; Humans; Losartan; Stroke; Treatment Outcome

2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diuretics; Humans; Hypertension; Losartan; Research Design

2002
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
    MMW Fortschritte der Medizin, 2002, May-16, Volume: 144, Issue:20

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Survival Rate

2002
No morbidity-mortality. Commentary.
    Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19 Suppl 5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Morbidity; Patient Selection

2002
[Preventing stroke. Which antihypertensive drugs can do it better?].
    MMW Fortschritte der Medizin, 2002, Jul-26, Volume: 144, Issue:29-30

    Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome

2002
[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
    Revista espanola de cardiologia, 2002, Volume: 55, Issue:9

    Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Research Design

2002
Was the LIFE trial independent?
    Lancet (London, England), 2002, Oct-12, Volume: 360, Issue:9340

    Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Research Support as Topic; Survival Rate; Sweden; Treatment Outcome

2002
Was the LIFE trial independent?
    Lancet (London, England), 2002, Oct-12, Volume: 360, Issue:9340

    Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Research Support as Topic; Survival Rate; Sweden; Treatment Outcome

2002
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
    MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Receptor, Angiotensin, Type 1; Survival Rate; Systole; Treatment Outcome

2002
[German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1

2002
[What are the consequences of the LIFE Study for general practice].
    MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1

2002
Differential effects of antihypertensive drug therapy on arterial compliance.
    American journal of hypertension, 2002, Volume: 15, Issue:12

    Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Treatment Outcome; Vascular Resistance

2002
New strategies for prevention of ischemic stroke: the LIFE study.
    Current neurology and neuroscience reports, 2003, Volume: 3, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome

2003
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
    MMW Fortschritte der Medizin, 2002, Oct-17, Volume: 144, Issue:42

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cause of Death; Coronary Disease; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic

2002
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
    Circulation, 2003, Jan-21, Volume: 107, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Carbazoles; Carvedilol; Drug Approval; Humans; Hypertension; Losartan; Middle Aged; Myocardial Infarction; Propanolamines; Racial Groups; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk; Stroke; Treatment Outcome; United States; United States Food and Drug Administration

2003
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
    Nederlands tijdschrift voor geneeskunde, 2003, Jan-18, Volume: 147, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Treatment Outcome

2003
More on the LIFE study.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Survival Rate; Sweden

2003
More on the LIFE study.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Data Collection; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Sweden

2003
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    JAMA, 2003, Feb-12, Volume: 289, Issue:6

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Losartan; Stroke

2003
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    JAMA, 2003, Feb-12, Volume: 289, Issue:6

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Losartan; Stroke

2003
[Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Deutsche medizinische Wochenschrift (1946), 2003, Jan-24, Volume: 128, Issue:4

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Time Factors

2003
[Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
    MMW Fortschritte der Medizin, 2003, Jan-16, Volume: 145, Issue:1-2

    Topics: Aged; Antihypertensive Agents; Atenolol; Cause of Death; Double-Blind Method; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate

2003
The LIFE study: the straw that should break the camel's back.
    European heart journal, 2003, Volume: 24, Issue:6

    Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke

2003
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Cause of Death; Clinical Trials as Topic; Humans; Hypertension; Losartan; Receptor, Angiotensin, Type 1; Treatment Outcome

2003
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
    Annals of internal medicine, 2003, Aug-05, Volume: 139, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged

2003
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Female; Humans; Hypertension; Losartan; Male

2003
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male

2003
[LIFE study proves preventive action. With losartan to do even more against stroke].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Double-Blind Method; Electrocardiography; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Time Factors

2003
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke

2003
Losartan and atenolol on hypertension induced by adenosine receptor blockade.
    Autonomic & autacoid pharmacology, 2003, Volume: 23, Issue:2

    Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 2 Receptor Blockers; Animals; Atenolol; Cell Division; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Hypertension; Infusion Pumps, Implantable; Infusions, Parenteral; Losartan; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Myocardium; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Receptors, Adrenergic, beta-1; Receptors, Purinergic P1; Renin; Tail; Xanthines

2003
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
    Stroke, 2003, Volume: 34, Issue:11

    Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Losartan; Ramipril; Stroke

2003
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
    Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Basement Membrane; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Hypertrophy; Kidney Failure, Chronic; Kidney Glomerulus; Losartan; Male; Microscopy, Electron; Nephrectomy; Proteinuria; Rats; Rats, Wistar; Systole; Time Factors

2003
LIFE: losartan versus atenolol.
    Lancet (London, England), 2003, Oct-25, Volume: 362, Issue:9393

    Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome

2003
LIFE: losartan versus atenolol.
    Lancet (London, England), 2003, Oct-25, Volume: 362, Issue:9393

    Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Fibrinolytic Agents; Humans; Hypertension; Losartan; Treatment Outcome

2003
The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives.
    Journal of hypertension, 2003, Volume: 21, Issue:11

    Topics: Adenine; Adult; Aged; Alleles; Antihypertensive Agents; Atenolol; Collagen Type I; Cytosine; Elasticity; Female; Gene Frequency; Genotype; Heart; Humans; Hypertension; Losartan; Male; Middle Aged; Polymorphism, Genetic; Receptor, Angiotensin, Type 1

2003
Proportion of treatment effect (PTE) explained by a surrogate marker.
    Statistics in medicine, 2003, Nov-30, Volume: 22, Issue:22

    Topics: Antihypertensive Agents; Atenolol; Biomarkers; Confidence Intervals; Data Interpretation, Statistical; Humans; Hypertension; Losartan; Models, Statistical; Monte Carlo Method; Treatment Outcome; Uric Acid

2003
[To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschritte der Medizin, 2003, Nov-06, Volume: 145, Issue:45

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Humans; Hypertension; Losartan; Middle Aged; Patient Compliance; Risk Factors; Stroke

2003
Effects of losartan in hypertension without vascular disease.
    Annals of internal medicine, 2004, Apr-06, Volume: 140, Issue:7

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Losartan

2004
The LIFE Trial in 2004.
    Journal of human hypertension, 2004, Volume: 18, Issue:6

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Losartan

2004
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:1

    Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Analysis

2004
Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure.
    Nephron. Experimental nephrology, 2004, Volume: 97, Issue:2

    Topics: Animals; Atenolol; Disease Models, Animal; Kidney; Kidney Cortex; Kidney Failure, Chronic; Losartan; Nephrectomy; Oxidative Stress; Rats

2004
[When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
    MMW Fortschritte der Medizin, 2004, Feb-12, Volume: 146, Issue:7

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Causality; Clinical Trials as Topic; Humans; Hypertension; Losartan; Patient Education as Topic; Risk; Stroke; Treatment Refusal

2004
[Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
    MMW Fortschritte der Medizin, 2004, Apr-29, Volume: 146, Issue:18

    Topics: Alzheimer Disease; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; Humans; Hypertension; Losartan; Treatment Outcome

2004
[Optimizing antihypertensive therapy. In 5 years 35,000 strokes are preventable].
    MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; Cross-Sectional Studies; Europe; Humans; Hypertrophy, Left Ventricular; Losartan; Middle Aged

2004
[A problem that should be recognized. Greater risk of diabetes with antihypertensive drugs?].
    MMW Fortschritte der Medizin, 2004, Dec-16, Volume: 146, Issue:51-52

    Topics: Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucose Tolerance Test; Humans; Losartan; Randomized Controlled Trials as Topic; Risk Factors

2004
Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:5

    Topics: Aged; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; Hypertension; Life Expectancy; Losartan; Male; Pharmacoepidemiology; Retrospective Studies; Switzerland

2004
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Journal of the American College of Cardiology, 2005, Mar-01, Volume: 45, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Cause of Death; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Survival Rate

2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke

2005
Keeping tabs on your heart while treating BP.
    The Johns Hopkins medical letter health after 50, 2005, Volume: 17, Issue:3

    Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan

2005
Letter regarding article by Devereux et al, "regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial".
    Circulation, 2005, Jun-07, Volume: 111, Issue:22

    Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Ventricular Function, Left

2005
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Journal of hypertension, 2005, Volume: 23, Issue:7

    Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; National Health Programs; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Sweden; Treatment Outcome

2005
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atenolol; Blood Pressure; Cardiomegaly; Doxazosin; Drug Therapy, Combination; Echocardiography; Heart Rate; Hypertension; Losartan; Male; Natriuretic Peptide, Brain; Rats; Rats, Inbred SHR; RNA, Messenger

2005
Pulse pressure and antihypertensive agents.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension; Losartan; Stroke

2005
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Atenolol; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk; Stroke

2005
Enlarged hearts, larger threats. But reducing heart-muscle mass can blunt cardiac dangers.
    Heart advisor, 2005, Volume: 8, Issue:4

    Topics: Antihypertensive Agents; Atenolol; Humans; Hypertrophy, Left Ventricular; Losartan

2005
Black pearl in the LIFE study: angiotensin-II receptor blockade on atrial fibrillation for future personalized medicine.
    Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Black or African American; Humans; Losartan; Recurrence; White People

2005
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Journal of hypertension, 2006, Volume: 24, Issue:4

    Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Creatinine; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome

2006
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
    PharmacoEconomics, 2006, Volume: 24, Issue:4

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies; Cost-Benefit Analysis; Critical Care; Female; Health Care Costs; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Models, Economic; Myocardial Infarction; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Stroke Rehabilitation

2006
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
    MMW Fortschritte der Medizin, 2006, Mar-16, Volume: 148, Issue:11

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Diseases; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Metabolic Syndrome; Primary Prevention; Prognosis; Risk Assessment; Risk Factors; Time Factors

2006
[Plus point -- risk reduction].
    MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Losartan; Placebos; Risk; Risk Factors; Stroke; Time Factors

2006
[Kidney protection leads to heart protection, too].
    MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Kidney Diseases; Losartan; Risk Factors; Time Factors

2006
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
    American journal of hypertension, 2006, Volume: 19, Issue:10

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Autonomic Nervous System; Blood Pressure; Cardiovascular System; Heart Rate; Hydrochlorothiazide; Hypertension; Losartan; Male; Ramipril; Rats; Rats, Wistar; Sympathetic Nervous System

2006
[Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Ugeskrift for laeger, 2006, Oct-16, Volume: 168, Issue:42

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Decision Trees; Health Care Costs; Humans; Hypertension; Losartan; Models, Economic; Quality-Adjusted Life Years

2006
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:6

    Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Losartan; Manometry; Perindopril; Ultrasonography, Doppler

2007
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Mellitus; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome

2007
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.
    Blood pressure, 2007, Volume: 16, Issue:6

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1

2007
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
    MMW Fortschritte der Medizin, 2008, Jan-17, Volume: 150, Issue:1-2

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Diabetes Complications; Drug Therapy, Combination; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk Factors; Stroke

2008
Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
    Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Capillaries; Disease Models, Animal; Enalapril; Heart Ventricles; Hypertension; Losartan; Male; Microcirculation; Microscopy, Video; Muscle, Skeletal; Nifedipine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Skin

2008
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
    American journal of hypertension, 2008, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Brachial Artery; Cardiac Volume; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Pulse; Ventricular Function

2008
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
    European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2008, Volume: 9, Issue:6

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ultrasonography

2008
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
    Vascular health and risk management, 2008, Volume: 4, Issue:1

    Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; France; Humans; Hydrochlorothiazide; Hypertension; Indapamide; Losartan; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan

2008
Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs.
    American journal of hypertension, 2009, Volume: 22, Issue:10

    Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Captopril; Hydrochlorothiazide; Losartan; Mice; Nifedipine; RNA, Messenger; Telmisartan

2009
Slower heart rates for healthy hearts: time to redefine tachycardia?
    Circulation. Arrhythmia and electrophysiology, 2008, Volume: 1, Issue:5

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Electrocardiography; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Reference Values; Risk Assessment; Risk Factors; Tachycardia; Time Factors; Treatment Outcome

2008
Effects of anti-hypertensive drugs on esophageal body contraction.
    World journal of gastroenterology, 2010, Feb-28, Volume: 16, Issue:8

    Topics: Adult; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Esophagus; Gastrointestinal Motility; Humans; Losartan; Male; Muscle, Smooth; Nifedipine; Peristalsis; Sympatholytics

2010
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    American journal of hypertension, 2010, Volume: 23, Issue:7

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic

2010
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Blood pressure, 2010, Volume: 19, Issue:3

    Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, HDL; Electrocardiography; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Regression Analysis; Risk

2010
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Blood pressure, 2010, Volume: 19, Issue:3

    Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Electrocardiography; Female; Heart Atria; Heart Rate; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk

2010
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Journal of human hypertension, 2011, Volume: 25, Issue:3

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Smoking; Stroke; Treatment Outcome

2011
Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data.
    BMC cardiovascular disorders, 2010, Jun-09, Volume: 10

    Topics: Antihypertensive Agents; Atenolol; Captopril; Cardiovascular Diseases; Cost of Illness; Developing Countries; Health Services Accessibility; Humans; Hydrochlorothiazide; Losartan; Nifedipine; World Health Organization

2010
Is hydrochlorothiazide more effective on LVH in nonresponders to losartan than in those to atenolol?
    American journal of hypertension, 2010, Volume: 23, Issue:7

    Topics: Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hydrochlorothiazide; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome

2010
Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol.
    American journal of hypertension, 2010, Volume: 23, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Atenolol; Hypertension; Losartan; Male; Malondialdehyde; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery; Renin-Angiotensin System; Sodium Chloride, Dietary; Superoxides

2010
Simultaneous spectrophotometric estimation of Hydrochlorothiazide, Atenolol and Losartan potassium in tablet dosage form.
    Hindustan antibiotics bulletin, 2009, Volume: 51, Issue:1-4

    Topics: Antihypertensive Agents; Atenolol; Calibration; Hydrochlorothiazide; Losartan; Spectrophotometry, Ultraviolet; Tablets

2009
Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2011, Volume: 33, Issue:2

    Topics: Adult; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Atenolol; Captopril; Case-Control Studies; Female; Humans; Hydrochlorothiazide; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-1beta; Lipopolysaccharides; Losartan; Male; Middle Aged; Neutrophils

2011
Effects of antihypertensive drugs on specific harmonic indices of the pulse waveform in normotensive Wistar Kyoto rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2012, Volume: 34, Issue:1

    Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Losartan; Male; Models, Animal; Models, Cardiovascular; Pulsatile Flow; Rats; Rats, Inbred WKY

2012
An economic evaluation of antihypertensive therapies based on clinical trials.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:1

    Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Costs; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic

2012
Blockade of renin-angiotensin system prevents micturition dysfunction in renovascular hypertensive rats.
    European journal of pharmacology, 2014, Sep-05, Volume: 738

    Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Captopril; Cyclic AMP; Electric Stimulation; Female; Hypertension, Renovascular; Losartan; Male; Muscle Relaxation; Rats; Renin-Angiotensin System; Urethra; Urinary Bladder; Urination

2014
Of Marfan's syndrome, mice, and medications.
    The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome

2014
Atenolol versus Losartan in Marfan's Syndrome.
    The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome

2015
Atenolol versus Losartan in Marfan's Syndrome.
    The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome

2015
Atenolol versus Losartan in Marfan's Syndrome.
    The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome

2015
Atenolol versus Losartan in Marfan's Syndrome.
    The New England journal of medicine, 2015, 03-05, Volume: 372, Issue:10

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome

2015
[Drugs news].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2015, Volume: 22, Issue:11

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Anticonvulsants; Aorta; Aortic Aneurysm; Atenolol; Cleft Palate; Female; Fructose; Hemangioma; Humans; Losartan; Male; Marfan Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Skin Neoplasms

2015
Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al.
    Vascular medicine (London, England), 2016, Volume: 21, Issue:1

    Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome; Vascular Stiffness

2016
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Journal of hypertension, 2016, Volume: 34, Issue:9

    Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Female; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Random Allocation; Risk Factors; Stroke

2016
Thermodynamic compatibility between cyclodextrin supramolecular complexes and surfactant.
    International journal of pharmaceutics, 2018, Jun-10, Volume: 544, Issue:1

    Topics: Antihypertensive Agents; Atenolol; beta-Cyclodextrins; Losartan; Magnetic Resonance Spectroscopy; Sodium Dodecyl Sulfate; Spectroscopy, Fourier Transform Infrared; Surface-Active Agents; Thermodynamics

2018
Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe?
    Environmental toxicology and pharmacology, 2018, Volume: 63

    Topics: Antihypertensive Agents; Atenolol; Brazil; Captopril; Cell Survival; Cells, Cultured; DNA Damage; Dose-Response Relationship, Drug; Enalapril; Government Programs; Humans; Hydrochlorothiazide; Hypertension; Losartan; Lymphocytes; Macrophages; Male; Mutagenicity Tests; Program Evaluation; Propranolol

2018
Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.
    The American journal of cardiology, 2018, 10-15, Volume: 122, Issue:8

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Arrhythmias, Cardiac; Atenolol; Child; Child, Preschool; Echocardiography; Electrocardiography, Ambulatory; Female; Humans; Infant; Losartan; Male; Marfan Syndrome; Retrospective Studies

2018
Losartan for the Treatment of Marfan Syndrome: Hope Fades.
    Journal of the American College of Cardiology, 2018, 10-02, Volume: 72, Issue:14

    Topics: Angiotensin II Type 1 Receptor Blockers; Atenolol; Dilatation; Humans; Losartan; Marfan Syndrome

2018
Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience.
    Clinical trials (London, England), 2020, Volume: 17, Issue:6

    Topics: Adolescent; Anti-Arrhythmia Agents; Atenolol; Black or African American; Child; Child, Preschool; Clinical Protocols; Female; Humans; Infant; Losartan; Male; Marfan Syndrome; Medication Adherence; Patient Compliance; Patient Selection; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Young Adult

2020
Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta.
    The American journal of cardiology, 2021, 04-01, Volume: 144

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atenolol; Bicuspid Aortic Valve Disease; Child; Child, Preschool; Dilatation, Pathologic; Female; Humans; Infant; Infant, Newborn; Losartan; Male; Pilot Projects; Retrospective Studies; Young Adult

2021
Racial and ethnic differences in response to treatment for Marfan syndrome.
    Cardiology in the young, 2021, Volume: 31, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Aorta; Atenolol; Child; Humans; Losartan; Marfan Syndrome; Young Adult

2021
Comparative Effect of Losartan and Atenolol on Heart Rate Variability in Untreated Essential Hypertensive Patients by Power Spectral Analysis.
    Mymensingh medical journal : MMJ, 2022, Volume: 31, Issue:2

    Topics: Adult; Atenolol; Bangladesh; Heart Rate; Humans; Longitudinal Studies; Losartan; Male; Middle Aged

2022
First report on the occurrence of pharmaceuticals and cocaine in the coastal waters of Santa Catarina, Brazil, and its related ecological risk assessment.
    Environmental science and pollution research international, 2022, Volume: 29, Issue:42

    Topics: Acetaminophen; Atenolol; Brazil; Caffeine; Carbamazepine; Chromatography, Liquid; Cocaine; Cosmetics; Diclofenac; Ecosystem; Environmental Monitoring; Humans; Losartan; Orphenadrine; Pharmaceutical Preparations; Risk Assessment; Sewage; Solid Waste; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical

2022
Occurrence, ecological risk assessment and prioritization of pharmaceuticals and abuse drugs in estuarine waters along the São Paulo coast, Brazil.
    Environmental science and pollution research international, 2022, Volume: 29, Issue:59

    Topics: Acetaminophen; Atenolol; Brazil; Caffeine; Carbamazepine; Chromatography, Liquid; Cocaine; Diclofenac; Ecosystem; Environmental Monitoring; Furosemide; Illicit Drugs; Losartan; Orphenadrine; Pharmaceutical Preparations; Risk Assessment; Rivers; Tandem Mass Spectrometry; Water Pollutants, Chemical

2022